SJF-620

N/A

Report date: 2022/01/14 13:23:58

NME

Base Information

Drug NameSJF-620

Drug Alias NameSJF-620

ClassificationSmall molecules > Proteolysis-Targeting Chimera (PROTAC)

Mechanisms of ActionTyrosine-protein kinase BTK inhibitorsProteolysis

TargetsTyrosine-protein kinase BTK

Therapy Area/IndicationsLeukemia, Lymphocytic, Chronic, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesYale University

China Registration ClassN/A

Active CompaniesYale University

Inactive CompaniesN/A

Active IndicationsLeukemia, Lymphocytic, Chronic, B-Cell

Inactive IndicationsN/A

ATC CodeN/A